Purple Biotech Ltd. - American Depositary Shares (PPBT)
1.9800
+0.00 (0.00%)
NASDAQ· Last Trade: Sep 3rd, 6:02 AM EDT
Detailed Quote
Previous Close
1.980
Open
-
Bid
1.840
Ask
1.890
Day's Range
N/A - N/A
52 Week Range
1.160 - 19.40
Volume
91,229
Market Cap
34.08M
PE Ratio (TTM)
-
EPS (TTM)
-
Dividend & Yield
N/A (N/A)
1 Month Average Volume
3,410,524
Chart
About Purple Biotech Ltd. - American Depositary Shares (PPBT)
Purple Biotech Ltd is a biotechnology company focused on the development of innovative therapies for cancer treatment. Its primary goal is to create a pipeline of drug candidates that leverage its proprietary technology to enhance the efficacy of existing cancer treatments while minimizing associated side effects. By utilizing cutting-edge research and clinical expertise, the company aims to address unmet medical needs in oncology and improve the quality of life for patients battling various forms of cancer. Through strategic collaborations and a commitment to scientific advancement, Purple Biotech strives to bring transformative solutions to the market. Read More
September 2, 2026 - Peraso Inc. (NASDAQ: PRSO) could be positioned for an emerging opportunity across military robotics, autonomous systems and secure tactical communications as the U.S. Army advances its Infantry Last Tactical Mile initiative for robotic tactical resupply, casualty evacuation (CASEVAC) and network extension .
REHOVOT, Israel, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or the “Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing a next-generation immunotherapy platform designed to maximize anti-cancer activity while minimizing toxicity, today announced that the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for a patent application covering tri-specific antibody constructs and methods of use. The patent allowance further expands the Company's intellectual property portfolio supporting its proprietary CAPTN-3 platform for conditionally activated multispecific antibodies.
Non-human primate (NHP) toxicology study validates the CAPTN-3 masking strategy, with IM1240 showing an 8-fold longer half-life, 16-fold greater exposure, and a markedly improved cytokine-release safety profile compared to the non-capped variant
Data, generated in the lab of Dr. Amir Horowitz of the Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai, demonstrated that all tested patient-derived tumor samples (n=7) responded to IM1240 treatment
Scientific Advisory Board (SAB) includes experts in the development and approved T-cell engager therapies, supporting CAPTN-3’s advancement toward clinical-stage immunotherapy development
Let's have a look at what is happening on the US markets after the closing bell on Tuesday. Below you can find the top gainers and losers in today's after hours session.
Data demonstrates the significant and sustained tumor regression achieved by the CAPTN-3 platform across two distinct tri-specific antibodies, IM1240 and IM1305, targeting different tumor antigens
New data showcase the versatility and anti-tumor activity of the CAPTN-3 platform and its unique multi-arm design in treatment-resistant cancers REHOVOT, Israel, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech” or “the Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance, today announced that it will present new preclinical data from its CAPTN-3 platform of conditionally activated tri-specific antibodies at the upcoming European Society of Medical Oncology Immuno-Oncology (ESMO-IO) 2025 Annual Congress being held from December 10–12, 2025, in London, United Kingdom.
The US market is yet to commence its session on Thursday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.
Stay up-to-date with the latest market trends in the middle of the day on Wednesday. Explore the top gainers and losers during today's session in our detailed report.
